Bloomberg News

Sanofi Says Lemtrada Helps More MS Patients Than Rebif in Trial

October 22, 2011

Oct. 22 (Bloomberg) -- Sanofi’s experimental drug Lemtrada worked better than an older medicine in preventing relapses from multiple sclerosis after two years, the company said.

A late-stage clinical trial comparing Lemtrada to Merck KGaA’s Rebif showed that 78 percent of the patients taking Lemtrada were relapse free after two years, compared with 59 percent who received Rebif, Paris-based Sanofi said in a statement today.

Sanofi reported preliminary results from the trial, dubbed CARE-MS I, in July. The company said then that Lemtrada cut relapse rates by 55 percent over two years compared with Rebif. The study is being presented today at a medical conference in Amsterdam.

Results from a second advanced-stage clinical trial for Lemtrada will be available before the end of the year, Sanofi said. The company plans to seek regulatory approval for the drug in the U.S. and European Union in the first quarter of 2012, Sanofi said.

--Editors: Tom Lavell, Robert Valpuesta

To contact the reporter on this story: Phil Serafino in Paris at pserafino@bloomberg.net

To contact the editor responsible for this story: Phil Serafino at pserafino@bloomberg.net


Steve Ballmer, Power Forward
LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus